# Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

> **NCT02903771** · PHASE1 · COMPLETED · sponsor: **Kazia Therapeutics Limited** · enrollment: 32 (actual)

## Conditions studied

- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms

## Interventions

- **DRUG:** Part A: Dose Escalation of Cantrixil
- **DRUG:** Part B: Expansion Cohort of Cantrixil

## Key facts

- **NCT ID:** NCT02903771
- **Lead sponsor:** Kazia Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2020-03-24
- **Final completion:** 2020-03-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903771, "Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02903771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*